Ingredient or product comparison
Peptides for Cosmetic Surgery Recovery Protocol Evidence Guide: Comparison Table
Before integrating any peptide into a recovery protocol, understanding mechanism, timing, and evidence strength is essential. The table below compares the three most commonly used compounds. BPC-157 VEGF upregulation, angiogenesis, cytokine reduction Days 1–21
This source-based comparison does not add ratings or recommend a winner.
- Before integrating any peptide into a recovery protocol, understanding mechanism, timing, and evidence strength is essential. The table below compares the three most commonly used compounds.
- BPC-157
- VEGF upregulation, angiogenesis, cytokine reduction
- Days 1–21 (proliferative phase)
- 250–500 mcg daily subcutaneous
- Animal tendon/ligament studies, no human surgical trials
- Strongest pre-clinical wound-healing data; dosing empirical
- TB-500
- Actin regulation, cell migration, MMP modulation
- Days 3–28 (proliferation and early remodeling)
- 2–5 mg twice weekly subcutaneous
- Cardiac and vascular repair in animals; keratinocyte migration in vitro
- Mechanism supports wound repair; human dosing extrapolated
- GHK-Cu
- Collagen synthesis, TGF-β signaling, antioxidant activity
- Weeks 3–12 (remodeling phase)
- 1–3 mg topical or 0.5–1.5 mg subcutaneous daily
- Human dermatology trials for photoaging; no surgical recovery trials
- Only peptide with direct human skin data; remodeling-phase specific